Medthority

💛 This #BladderHealthMonth, explore the latest in #BladderCancer care. Access expert resources on diagnosis, management and emerging insights across #NMIBC and advanced disease, including our podcast hosted by @UroDocAsh ow.ly/9oQw5104Y7h

🫁 Catch up on the latest lung cancer highlights from #ESMO26. Explore key congress updates, expert insights and developments shaping the evolving treatment landscape of small-cell lung cancer (SCLC) and non–small-cell lung cancer (NSCLC) care ow.ly/PO7A51040hy

🫁 November is Lung Cancer Awareness Month. Keep up with the evolving treatment landscape with our Lung Cancer Nexus, and follow our socials for key resources throughout the month, including highlights from this year's WCLC, ASCO and ESMO congresses ow.ly/WGXB5103ZYP

📰 It’s News-day Tuesday! New research highlights rising colorectal cancer rates across US adults and potential biological differences in younger patients. Plus, a targeted therapy combination shows promising survival outcomes in advanced kidney cancer ow.ly/TSFZ5103kHY

Press play on the latest medical updates with Medthority’s YouTube channel. Explore expert interviews, podcasts, and congress highlights covering the topics that matter in clinical practice youtube.com/@Medthority

Earn up to 70 minutes EBAC® CME credit and watch Benedikt Schoser, Derralynn Hughes, Christoph Wanner, and Karim Wahbi discuss Fabry management from childhood through to older adulthood ow.ly/OEOt5101CjB

Keep up with the conversations that matter in medicine with Medthority. Explore independent medical education, expert insights, congress highlights, and clinical resources created to support your practice ow.ly/nR495101est

📰 It’s News-day Tuesday! New research highlights the benefits of continuous glucose monitoring for people with type 2 diabetes who do not use insulin. Plus, scientists reveal that ovaries remain biologically active after menopause ow.ly/mi605100Z5g

This #LiverAwarenessMonth, explore the latest updates in alpha-1 antitrypsin deficiency (AATD) diagnosis, management and care with Medthority. Access expert perspectives and educational resources to support your clinical practice ow.ly/FoZF5100Tga

That wraps our #ESMO26 coverage! If you missed any updates, head over to Medthority to catch up on expert insights and the highlights you need to know in lung cancer #Oncology #OncTwitter #MedX #MedEd ow.ly/qPJA5100Zio

#ESMO26 ASTRIDE provided US data supporting serplulimab in ES-SCLC, with outcomes consistent with the phase 3 ASTRUM-005 trial. 📊 2-year OS: 32.2% vs 17.6% 📊 Median PFS: 5.4 vs 4.9 months No new safety signals identified. #LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX

#ESMO26 The US bridging study ASTRIDE reported numerically longer overall survival with serplulimab plus chemotherapy versus atezolizumab plus chemotherapy in ES-SCLC. 📊 Median OS: 12.4 vs 10.2 months Presented by @drgandara #LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX

#ESMO26 Updated DeLLphi-304 data also showed sustained long-term benefit with tarlatamab in previously treated #SCLC. 📊 2-year OS: 30% vs 15% 📊 Sustained disease control ≥52 weeks: 24% vs 4% No new safety signals. #LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX #MedSky

#ESMO26 Extended follow-up from the phase 3 DeLLphi-304 trial showed durable survival benefit with tarlatamab in previously treated #SCLC. 📊 Median OS: 13.6 vs 8.4 months 📊 38% lower risk of death Presented by @charlesrudin #LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX

Next up, look out for our roundup of the key topics being discussed in the oral abstract session “Proffered paper session on non-metastatic NSCLC and other thoracic malignancies”, coming soon 👀

#ESMO26 Phase 1 data for SKB500, a B7-H3-targeted ADC, also demonstrated encouraging activity in heavily pretreated ES-SCLC. 📊 ORR: 62.5%-66.7% 📊 Median PFS: 5.6-8.1 months Presented by Haifeng Liu. #LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX #MedSky

#ESMO26 New data for ABBV-706, a first-in-class SEZ6-targeted ADC, showed promising activity in relapsed/refractory #SCLC. 📊 ORR: 56% at the recommended phase 3 dose 📊 Median OS: 12.4 months Presented by @Annechiangmd #LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX #MedSky

What’s new in non-metastatic #SCLC at #ESMO26? Get live updates and key takeaways on emerging ADCs from @Annechiangmd and Haifeng Liu #OncTwitter #MedEd #MedX #LungCancer #Oncology

🫁That’s a wrap on today’s metastatic NSCLC sessions at #ESMO26. For more insights from the event, check out news summaries written by our expert scientific team, on-demand with Medthority ow.ly/lsEU5100MpY

More from Shun Lu on SAFFRON study - osimertinib + savolitinib vs platinum-pemetrexed in adv #NSCLC after osimertinib: 📊 DoR: 9.7 vs 5.7 months 📊 Grade ≥3 TEAEs: 64% vs 63% 📊 TEAE discontinuation (all cause): 14% vs 8% #LungCancer #Oncology #OncTwitter #MedEd #MedX #MedSky